Open Label Study Of Intramuscular Olanzapine Depot In Patients With Schizophrenia Or Schizoaffective Disorder
Related Clinical Trials
Study to Evaluate the Intramuscular Depot Formulation of Aripiprazole in Patients with Schizophrenia
For patients with schizophrenia. All participants receive active medication in the double-blind study (247). Once randomized, they are eligible to participate in an open label study (248) of the Abilify long-acting depot for up to two years or when the medication is approved by the FDA.